Japanese and Indian M&As feature in 2005 pharma/biotech deals
2005 saw an increase in global merger and acquisition activity, with the value of worldwide, all-industry deals reaching a $2,900.0 billion high, up 38% on 2004. The biggest of all was Procter & Gamble's takeover of Gillette for $60.8 billion, although not as large as the previous year's $62.6 billion mega merger of France's Sanofi-Synthelabo and Franco-German group Aventis.
The pharmaceutical and biotechnology sector had its fair share of M&A activity in 2005 (see pages 8 and 9 for details), notable to some extent for the deals that did not go through (ie, several Indian drugmakers' attempts to buy US and European generic drug firms) and further consolidation of the Japanese pharmaceutical industry, which has followed the previous year's $8.0 billion merger of Yamanouchi and Fujisawa to create Astellas.
J&J bid for Guidant could falter
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze